Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.

[1]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[2]  P. Adeleine,et al.  Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Rich.  Camptothecin Radiation Sensitization , 2003 .

[4]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  A. Koong,et al.  Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. , 2003, International journal of radiation oncology, biology, physics.

[6]  A. Hinke,et al.  Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Barugel,et al.  Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. , 2002, International journal of radiation oncology, biology, physics.

[8]  K. Song,et al.  Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[9]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Martoni,et al.  [Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies]. , 2001, Tumori.

[12]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[13]  A. Norman,et al.  Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer , 2001, British Journal of Cancer.

[14]  J. Lotz,et al.  High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.

[15]  P. Romestaing,et al.  Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Hohenberger,et al.  Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94) , 2001, Strahlentherapie und Onkologie.

[18]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Breed,et al.  Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Bajetta,et al.  [New drugs in the therapy of colorectal cancer]. , 2001, Tumori.

[21]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[22]  C. Tournigand,et al.  Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Garcia-Aguilar.  Commentary on 'Current protocols and outcomes of local therapy for rectal Cancer' by bleday and steele , 2000, Surgical oncology clinics of North America.

[24]  G. Steele,et al.  Current protocols and outcomes of local therapy for rectal cancer. , 2000, Surgical oncology clinics of North America.

[25]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[26]  J. Ellenhorn,et al.  Transanal Excision for Low Rectal Cancers is Curative in Early-Stage Disease with Favorable Histology , 2000, The American surgeon.

[27]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Gamelin,et al.  Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[30]  P. Tofilon,et al.  Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. , 2000, Cancer research.

[31]  M. Sprangers,et al.  Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes , 2000, British Journal of Cancer.

[32]  J. Horiot,et al.  Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. , 2000, International journal of radiation oncology, biology, physics.

[33]  B. Fisher,et al.  Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. , 2000, International journal of radiation oncology, biology, physics.

[34]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[36]  J. Misset,et al.  Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function , 2000, Cancer Chemotherapy and Pharmacology.

[37]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[38]  Y. Rustum,et al.  New drugs in therapy of colorectal cancer: preclinical studies. , 1999, Seminars in oncology.

[39]  M. Ducreux,et al.  Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  K. Seibert,et al.  COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.

[41]  H. Choy,et al.  DNA topoisomerase I-targeting drugs as radiation sensitizers. , 1999, Oncology.

[42]  P. Tofilon,et al.  Enhancement of Tumor Response to γ-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme , 1999 .

[43]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[44]  J. Guillem,et al.  Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. , 1999, International journal of radiation oncology, biology, physics.

[45]  C. Compton,et al.  Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. , 1999, Annals of surgery.

[46]  A. Benson,et al.  Sphincter-Sparing Treatment for Distal Rectal Adenocarcinoma , 1999, Annals of Surgical Oncology.

[47]  R. Weichselbaum,et al.  Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. , 1998, Cancer research.

[48]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[49]  C. Tournigand,et al.  Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[51]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[52]  T. Rich,et al.  Camptothecin radiation sensitization: mechanisms, schedules, and timing. , 1998, Oncology.

[53]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[54]  H. Ishitsuka,et al.  Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine). , 1998, Biological & pharmaceutical bulletin.

[55]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[56]  H. Ishitsuka,et al.  Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. , 1998, Cancer research.

[57]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[58]  J. Tepper,et al.  Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. DuBois,et al.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Fukuoka,et al.  Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts , 1997, Japanese journal of cancer research : Gann.

[61]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[62]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[63]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[64]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[65]  Y. Ueno,et al.  Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma. , 1996, Biological & pharmaceutical bulletin.

[66]  B. Eisenberg,et al.  Long-term follow-up of local excision and radiation therapy for invasive rectal cancer , 1995, Diseases of the colon and rectum.

[67]  J. Ajani,et al.  Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. , 1995, International journal of radiation oncology, biology, physics.

[68]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[69]  M. Anscher,et al.  Preoperative Radiation and Chemotherapy in the Treatment of Adenocarcinoma of the Rectum , 1995, Annals of surgery.

[70]  W. Enker,et al.  Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. , 1995, International journal of radiation oncology, biology, physics.

[71]  T. Lawrence,et al.  Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. , 1995, International Journal of Radiation Biology.

[72]  J. Fleshman,et al.  Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. , 1995, International journal of radiation oncology, biology, physics.

[73]  H. Wieand,et al.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. , 1994, The New England journal of medicine.

[74]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[75]  T. Lawrence,et al.  Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. , 1994, International journal of radiation oncology, biology, physics.

[76]  C. Hennequin,et al.  Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. , 1994, Cancer research.

[77]  C. Wong,et al.  Local excision and post-operative radiation therapy for rectal carcinoma. , 1993, International journal of radiation oncology, biology, physics.

[78]  S. Chaney,et al.  Role of carrier ligand in platinum resistance of human carcinoma cell lines. , 1993, Cancer research.

[79]  B. Teicher,et al.  Interaction of topoisomerase I inhibitors with radiation in cis‐diamminedichloroplatinum(II)‐sensitive and ‐resistantcells In Vitro and in the fsaiic fibrosarcoma In Vivo , 1993, International journal of cancer.

[80]  L. Marnett.  Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.

[81]  C. Willett,et al.  Adjuvant Postoperative Radiation Therapy For Rectal Adenocarcinoma , 1992, American journal of clinical oncology.

[82]  R. Billingham,et al.  Conservative treatment of rectal cancer extending the indications , 1992, Cancer.

[83]  K. Bland,et al.  Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? , 1992, Annals of surgery.

[84]  T. Kinsella,et al.  Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. , 1992, Cancer research.

[85]  B. Minsky,et al.  Variables correlated with the risk of lymph node metastasis in early rectal cancer , 1992, Cancer.

[86]  W. Enker,et al.  Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  T. Lawrence,et al.  The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. , 1991, International journal of radiation oncology, biology, physics.

[88]  W. Meyers,et al.  Effective surgical adjuvant therapy for high-risk rectal carcinoma. , 1991, The New England journal of medicine.

[89]  T. Lawrence,et al.  Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. , 1990, International journal of radiation oncology, biology, physics.

[90]  C. Compton,et al.  Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  H. Rockette,et al.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. , 1988, Journal of the National Cancer Institute.

[92]  F. Valeriote,et al.  Schedule-dependent cytotoxicity of 5-fluorouracil in mice. , 1986, Journal of the National Cancer Institute.

[93]  J. Laskin,et al.  Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. , 1980, Cancer research.

[94]  Y. Nakajima,et al.  Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. , 1979, Cancer research.

[95]  D. Santi,et al.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. , 1974, Biochemistry.

[96]  F. Valeriote,et al.  Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells. , 1971, Journal of the National Cancer Institute.

[97]  C. Moertel,et al.  Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. , 1969, Lancet.

[98]  F. F. Gollin,et al.  Mechanisms of action of radiotherapy and chemotherapeutic adjuvants: A review , 1968, Cancer.

[99]  R. Berry.  Effects of some metabolic inhibitors on x-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated x-ray doses. , 1966, The British journal of radiology.

[100]  C. Heidelberger,et al.  Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. , 1958, Cancer research.